Testing for ME

The Company purchased all outstanding shares of Durata, which were valued at approximately $724.5 million, including the assumption of debt and there is one CVR per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata’s lead product Dalvance ... ................
................